Possibilities of the combination of avelumab and axitinib in the first line in patients with advanced renal cell carcinoma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Combination regimens based on immune checkpoint inhibitors demonstrate a significant advantage in the first line for metastatic kidney cancer. The results of the phase III randomized JAVELIN Renal 101 trial confirm the possibility of a significant improvement in progression-free survival and an increase in the objective response rate when prescribing the combination of avelumab and axitinib compared with sunitinib therapy in all subgroups of patients, regardless of the PD-L1 expression level and prognostic risk group. In the subgroup of patients with sarcomatoid component of kidney cancer who have the most unfavorable prognosis, the combination of avelumab and axitinib also provides improved efficacy compared with sunitinib.

Full Text

Restricted Access

About the authors

Anna I. Semenova

N.N. Petrov National Medical Research Center of Oncology

Email: mirannia@yandex.ru
Cand. Sci. (Med.), Senior Researcher Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, Oncologist at the Department of Antitumor Drug Therapy, Associate Professor at the Department of Additional Professional Education St. Petersburg, Russia

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

G. M Teletaeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. Kh Latipova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. V Novik

N.N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical University

St. Petersburg, Russia

References

  1. Sung H, Ferlay J., Siegel R.J., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality in 185 countries. CA Cancer J Clin. 2021;71:209-49. Doi: 10.3322/ caac.21660.
  2. Hirsch L, Flippot R., Escudier B., Albiges L. Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs. 20201169-81. doi: 10.1007/s40265-020-01327-7.
  3. Rassy E., Flippot R., Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 2020;12.1758835920907504. doi: 10.1177/1758835920907504.
  4. Choueiri T.K., Motzer R.J. Systemic Therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354-66. Doi: 10.1056/ NEJMra1601333.
  5. Zhu J., Armstrong A.J., Friedlander T.W., Kim W., et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018;25(6):4. doi: 10.1186/s40425-018-0314-1.
  6. Bosma N.A., Warkentin M.T., Gan C.L., et al. Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Open Sci. 2022;37:14-26. Doi: 10.1016/j. euros.2021.12.007.
  7. Choueiri T.K, Motzer R.J., Rini B.I., et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus Axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31:1030-39. Doi: 10.1016/j. annonc.2020.04.010.
  8. Motzer R.J., Penkov K., Haanen J., et al. Avelumab plus axitinib versus sunitinib for advanced renalcell carcinoma. N Engl J Med. 2019;80:1103-15. doi: 10.1056/NEJMoa1816047.
  9. Tomita Y, Motzer R.J., Choueiri T.K., et al. Efficacy and safety of avelumab and Axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. Ann Oncol. 2022;(2). Doi: 10.1016/j. esmoop.2022.100450.
  10. Kelly K., Infante J.R., Taylor M.H., et al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase I JAVELIN Solid Tumor and phase II JAVELIN Merkel 200 clinical trials. Cancer. 2018;124:2010-17. doi: 10.1002/cncr.31293.
  11. Choueiri T.K., Larkin J., Oya M., et al. Preliminary results for avelumab plus Axitinib as first-line therapy in patients with advanced clear-cell renalcell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expantion, phase 1b trial. Lancet Oncol. 2018;19:451-60. doi: 10.1016/S1470-2045(18)30107-4.
  12. Bakouny Z., Braun D.A., Shukla S.A. et al.Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021;12(1):808. Doi: 10.1038/ s41467-021-21068-9.
  13. Shuch B., Bratslavsky G., Linehan W.M., Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist. 2012;17:46-54. doi: 10.1634/theoncologist.2011-0227
  14. Choueiri T.K., Larkin J., Pal S., et al. Efficacy and correlative analyses of avelumab plus Axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. Ann Oncol. 2021;6(3). doi: 10.1016/j.esmoop.2021.100101
  15. Motzer R.J., Robbins P.B., Powles T., et al. Avelumab plus Axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 Javelin Renal 101 trial. Nat Med. 2020;26:1733-41. doi: 10.1038/s41591-020-1044-8.
  16. Lolli C., Altavill A., Condeduca V., et al. A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. Crit Rev Oncol Hematol. 2020;153:103036. Doi: 10.1016/j. critrevonc.2020.103036.
  17. Doroshow D.B., Bhalla S., Beasley M.B., et al. PD-L1 as a biomarker of response to immune-checkpoints inhibitors. Nat Rev Clin Oncol. 2021;18:345-62. doi: 10.1038/s41571-021-00473-5.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies